➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Boehringer Ingelheim
McKinsey
Harvard Business School
McKesson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Pfizer Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Pfizer

Drugs and US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer PFIZERPEN G penicillin g potassium TABLET;ORAL 060075-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Pfizer VANSIL oxamniquine CAPSULE;ORAL 018069-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Pfizer LYRICA pregabalin CAPSULE;ORAL 021446-006 Dec 30, 2004 AB RX Yes No   Start Trial   Start Trial
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Pfizer PFIZERPEN-AS penicillin g procaine INJECTABLE;INJECTION 060286-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Pfizer DAURISMO glasdegib maleate TABLET;ORAL 210656-001 Nov 21, 2018 RX Yes No 10,414,748   Start Trial Y Y   Start Trial
Pfizer TALZENNA talazoparib tosylate CAPSULE;ORAL 211651-001 Oct 16, 2018 RX Yes No 8,420,650   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer MERREM meropenem INJECTABLE;INJECTION 050706-001 Jun 21, 1996 4,943,569   Start Trial
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-003 Approved Prior to Jan 1, 1982 4,130,647   Start Trial
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-003 Approved Prior to Jan 1, 1982 4,092,315   Start Trial
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-007 Jan 30, 2004 5,273,995*PED   Start Trial
Pfizer PROCARDIA XL nifedipine TABLET, EXTENDED RELEASE;ORAL 019684-002 Sep 6, 1989 4,783,337   Start Trial
Pfizer DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER fluconazole INJECTABLE;INJECTION 019950-004 Jan 29, 1990 4,404,216*PED   Start Trial
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-010 Jul 29, 2004 4,572,909*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2009-04-07
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 2004-07-26
➤ Subscribe Capsules 75 mg, 100 mg and 125 mg ➤ Subscribe 2019-02-04
➤ Subscribe Oral Solution 20 mg/mL ➤ Subscribe 2010-05-19
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 2014-05-01
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe 2018-01-29
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe 2018-01-29
➤ Subscribe Extended-release Tablets 4 mg and 8 mg ➤ Subscribe 2012-10-31
➤ Subscribe Tablets 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg ➤ Subscribe 2006-12-29
➤ Subscribe Tablets 2.5 mg/40 mg ➤ Subscribe 2009-09-17
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2005-02-07
➤ Subscribe Capsules 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg ➤ Subscribe 2008-12-30
➤ Subscribe Capsules 5 mg and 10 mg ➤ Subscribe 2005-06-21
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2011-06-17
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe 2018-02-02
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe 2018-02-02
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 2016-11-07

Supplementary Protection Certificates for Pfizer Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2822953 122019000088 Germany   Start Trial PRODUCT NAME: LORLATINIB ODER PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1355 20190506
1453521 CA 2016 00016 Denmark   Start Trial PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
1666481 122017000062 Germany   Start Trial PRODUCT NAME: TOFACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1178 20170322
1481964 C 2007 098 Romania   Start Trial PRODUCT NAME: FUMARATACID DE FESOTERODINA IN FORMA CRISTALINA 2[(1R)-3-(DIIZOPROPILAMINO)-1-FENILPROPIL]-4-(HIDROXIMETIL)FENILIZOBUTIRIC INFORMA CRISTALINA - FUMARAT ACID DE FESOTERODINA IN FORMA CRISTALINA; NATIONAL AUTHORISATION NUMBER: RO EU/1/07/386/001, RO EU/1/07/386/002, RO EU/1/07/386/003, RO EU/1/07/386/004, RO EU/1/07/386/005, RO EU/1/07/386/006, RO EU/1/07/386/007, RO EU/1/07/386/008, RO EU/1/07/386/009, RO EU/1/07/386/010; DATE OF NATIONAL AUTHORISATION: 20070420; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/386/001, EU/1/07/386/002, EU/1/07/386/003, EU/1/07/386/004, EU/1/07/386/005, EU/1/07/386/006, EU/1/07/386/007, EU/1/07/386/0 [...]
1746976 CA 2017 00030 Denmark   Start Trial PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018
3412676 LUC00168 Luxembourg   Start Trial PRODUCT NAME: COMBINAISON DE VABORBACTAM, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, ET DE MEROPENEME, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, EN PARTICULIER DE MEROPENEME TRIHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/18/1334 20181122
0502314 SPC/GB11/010 United Kingdom   Start Trial PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Mallinckrodt
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.